Hamfjord J, Guren TK, Glimelius B, et al. - This study was undertaken to explore clinicopathological factors correlated with tumour-specific circulating cell-free DNA in plasma (ctDNA) in patients with RAS-/ BRAF -mutated metastatic colorectal cancer (mCRC) prior to first-line therapy and to assess the prognostic impact of ctDNA compared to other biomarkers. A total of 253 patients were enrolled in the NORDIC-VII study. The results showed that clinicopathological characteristics should be carefully considered when evaluating ctDNA outcomes from mCRC patients, particularly when confronted with a plasma negative result. ctDNA may prove to be a clinically beneficial marker in the assessment of mCRC treatment.